Erythropoietin: remodeling and glycoconjugation of erythropoietin

• US 8,716,240 B2
• Filed: 02/02/2007
• Issued: 05/06/2014
• Est. Priority Date: 10/10/2001
• Status: Expired due to Fees

• Current Assignee: Novo Nordisk A/S
• Original Assignee: Novo Nordisk A/S
• Inventors: DeFrees, Shawn, Zopf, David A., Bayer, Robert J., Bowe, Caryn, Hakes, David James, Chen, Xi
• Primary Examiner(s): GOON, SCARLETT Y
• Application Number:
  US11/701,949
• Publication Number:
  US 20080187955A1
• Time in Patent Office: 2,650 Days
• Field of Search: 514/8, 514/20.9
• US Class Current: 514/20.9
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61K 47/549 Sugars, nucleosides, nucleotides or nucleic acids
• CPC Class Codes: A61K 47/60 the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
• CPC Class Codes: A61K 47/61 the organic macromolecular compound being a polysaccharide or a derivative thereof
• CPC Class Codes: A61P 13/12 of the kidneys
• CPC Class Codes: A61P 7/06 Antianaemics
• CPC Class Codes: A61P 7/08 Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock artificial tears A61P27/04
• CPC Class Codes: C07K 14/505 Erythropoietin [EPO]
• CPC Class Codes: C12P 21/005 Glycopeptides, glycoproteins
• CPC Class Codes: Y02A 50/30 Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

The invention includes methods and compositions for remodeling a peptide molecule, including the addition or deletion of one or more glycosyl groups to a peptide, and/or the addition of a modifying group to a peptide.

Claims

1. An isolated covalent conjugate between an erythropoietin peptide and a water-soluble polymer, wherein

the covalent conjugate is prepared by a cell-free, in vitro method comprising:

(a) contacting an asialo erythropoietin peptide with a first glycosyltransferase and a first modified sugar donor under conditions suitable for said first glycosyltransferase to covalently attach a sugar moiety of said first modified sugar donor to a preselected first glycosyl residue of said erythropoietin peptide via a first intact glycosyl linking group, wherein said sugar moiety of said first modified sugar donor comprises one modifying group which is a first water-soluble polymer,

(b) contacting said erythropoietin peptide with a second glycosyltransferase and a second modified sugar donor under conditions suitable for said second glycosyltransferase to covalently attach a sugar moiety of said second modified sugar donor to a preselected second glycosyl residue of said erythropoietin peptide via a second intact glycosyl linking group, wherein said sugar moiety of said second modified sugar donor comprises one modifying group which is a second water-soluble polymer, thereby forming the covalent conjugate,

wherein

(i) said first glycosyltransferase and said second glycosyltransferase are independently selected from the group consisting of sialyltransferase, galactosyltransferase, and GalNAc transferase, and

(ii) said first water-soluble polymer and said second water-soluble polymer are selected from the group consisting of poly(ethers), poly(amines), and poly(carboxylic acids), and

(c) isolating the covalent conjugate,

thereby forming an isolated covalent conjugate, with the proviso that three or less glycosyl residues of said isolated covalent conjugate comprise a modifying group covalently attached thereto.

2. The isolated covalent conjugate of claim 1, wherein said first residue and said second residue are structurally identical.

3. The isolated covalent conjugate of claim 1, wherein said first residue and said second residue have different structures.

4. The isolated covalent conjugate of claim 1, wherein said first intact glycosyl linking group and said second intact glycosyl linking group are the same.

5. The isolated covalent conjugate of claim 1, wherein said first intact glycosyl linking group and said second intact glycosyl linking group are different.

6. The isolated covalent conjugate of claim 1, wherein each of said first intact glycosyl linking group and said second intact glycosyl linking group is a sialic acid residue.

7. The isolated covalent conjugate of claim 1, wherein said first glycosyltransferase and said second glycosyltransferase are the same.

8. The isolated covalent conjugate of claim 1, wherein said first glycosyltransferase and said second glycosyltransferase are different.

9. The isolated covalent conjugate of claim 1, wherein each of said first glycosyltransferase and said second glycosyltransferase is independently selected from the group consisting of ST3Gal3, ST3Gal1, ST6GalNAcI, CST-II and combinations thereof.

10. The isolated covalent conjugate of claim 1, wherein each of said first glycosyltransferase and said second glycosyltransferase is a sialyltransferase.

11. The isolated covalent conjugate of claim 1, wherein the first glycosyl residue and the second glycosyl residue are the only glycosyl residues of the erythropoietin peptide which comprise a modifying group covalently attached thereto.

12. The isolated covalent conjugate of claim 1, wherein each of said first water-soluble polymer and said second water-soluble polymer is a poly(ethylene glycol).

13. The isolated covalent conjugate of claim 12, wherein said first water-soluble polymer and said second water-soluble polymer are the same.

14. The isolated covalent conjugate of claim 12, wherein said first water-soluble polymer and said second water-soluble polymer are different.

15. The isolated covalent conjugate of claim 12, wherein said poly(ethylene glycol) is a monomethoxy-poly(ethylene glycol).

16. The isolated covalent conjugate of claim 12, wherein said poly(ethylene glycol) is a member selected from linear poly(ethylene glycol) and branched poly(ethylene glycol).

17. The isolated covalent conjugate of claim 12, wherein said poly(ethylene glycol) has a molecular weight distribution that is essentially homodisperse.

18. The isolated covalent conjugate of claim 1, said method further comprising, prior to step (c),

contacting said covalent conjugate with CMP-N-acetylneuraminic acid and a sialyltransferase under conditions suitable for said sialyltransferase to transfer N-acetylneuraminic acid onto said covalent conjugate, thereby transferring N-acetylneuraminic acid onto said covalent conjugate.

19. A population of the isolated covalent conjugates of claim 1, wherein at least 60% of the covalent conjugates are identical.

20. The population of claim 19, wherein at least 70% of the covalent conjugates of the population are identical.

21. The population of claim 19, wherein at least 80% of the covalent conjugates of the population are identical.

22. The population of claim 19, wherein at least 90% of the covalent conjugates of the population are identical.